The GILENYA™ Pregnancy Registry is intended to monitor outcomes in women who have taken fingolimod shortly before or during pregnancy since data are currently very limited.

If you are a physician interested in the registry, or if you want to enroll a patient, please follow the Physicians Tab.

Quintiles Outcome is a specialized research organization managing this pregnancy registry on behalf of Novartis the manufacturer of fingolimod.

If you are a patient and have taken fingolimod shortly before becoming pregnant (within 8 weeks of your last period) or during your pregnancy:

  • Tell your doctor right away. You and your doctor will decide what is best for you and your baby.
  • Important safety information can also be found in the Patient Information Leaflet in each pack of fingolimod. You should not breastfeed whilst taking fingolimod because it can pass into breast milk and there is a risk of serious side effects to your baby.
  • If you wish to enroll into this registry, contact your doctor as only he/she is able to enroll patients. If you are a patient from Canada, you can contact the registry with the Canadian toll free number.

This is an international Website.
This site is intended for a global audience.

©Copyright 2012. All rights reserved.

FTY.24.12b July 2012